FDA Approves Rinvoq for Giant Cell Arteritis Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication https://t.co/gPTwnR2VLw

RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?

Tuesday Night Rheumatology returns this month with the launch of Lupus Unlocked, starting with a special Journal Club session. Join authors Dr. Richard Furie and Dr. Brad Rovin as they walk us through their pivotal studies on lupus nephritis: 📄 Obinutuzumab in Active Lupus https://t.co/2zZOEzsnnI

TriNetX EMR ulation study of CV risk w/ biologics in Psoriasis pts shows signifcant reduced CV events in PsO pts taking r\TNFi (HR 0.886), IL-17i (HR 0.724), IL-23i (HR 0.739); not anti-IL-12/23 (HR 0.915); Risk reduction applied to all subgroups (age, comorbidity, Wt) https://t.co/67c5yqK80h

2024 Management of Familial Mediterranean Fever Recommendations A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based https://t.co/jZxCdXrDi6

Japan IORRA RA registry shows from 2011 to 2023, despite better Rx & control & less pred, Fractures went up in RA. From 2011 to 2023- DAS resmission 38 to 65%, bDMARD use 14 to 42%, GC use 38 to 22%, OP Rx 32 to 38%; But all FX incr 47 to 53/1000 Pys. https://t.co/cgz0Gkasai https://t.co/ziZr3BegDz

RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?